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background:  The efficacy of factor Xa inhibitors (FXIs) compared to vitamin K antagonists (VKAs) in the prevention of stroke and systemic 
emoblization (SE) in the setting of electrical cardioversion has been advocated based upon limited data.
Methods:  We evaluated the statistical power of individual historical (n=4) and ongoing (n=3) prospective studies as well as the potential of 
pooled data to assess the non-inferiority of FXIs compared to VKAs in stroke/SE prevention.
results:  Based on historical data, we assumed a 30 day background incidence of 0.4% for stroke/SE with VKA assignment and a non-
inferiority margin of 2.0 using a hazard ratio approach with a one-sided α= 0.025. The power of the 7 studies to rule out a doubling of the 
risk of stroke/SE with FXI assignment ranged from 4%-16%. A random-effects meta analysis of the 6,518 combined subjects historical or 
ongoing trials indicated that the predicted 26 strokes /SEs at 30 days would result in 43% power to demonstrate non-inferiority. Similar 
power limitations were present for bleeding risk. A sensitivity analysis of power and non-inferiority margins is depicted.
Conclusion:  Individual ongoing and historical non-inferiority-based comparisons of FXIs and VKAs are considerably underpowered. 
While still not approximating substantial power, pooling of data will increase statistical confidence of this drug class’s anti-embolic efficacy 
compared to VKAs.
Sample Size Sensitivity Analysis
Hazard Ration
Non-inferiority Margin Power (%) Strokes/SEs Required Subjects Required
Condition 1 2.0 80 66 16,300
Condition 2 2.0 90 88 21,800
Condition 3 1.5 80 191 47,600
Condition 4 1.5 90 255 63,700
